The Cambridge, Massachusetts-based company said it is discussing with the World Health Organization’s COVAX initiative a multi-level pricing proposal for the potential vaccine, now called mRNA-1273.
Moderna has already concluded agreements for deliveries in North America, the Middle East and other regions of the world.
“We are actively preparing to launch mRNA-1273 and have signed a number of delivery agreements with governments around the world. Moderna meets the highest standards of data quality and rigorous scientific research, while continuing to work with regulators to advance mRNA-1273, ”said Moderna CEO Stephane Bancel in a press release.
Moderna, which is leading the race to develop a vaccine for Covid-19, announced last week that it had completed the enrollment of 30,000 participants in a final phase clinical trial.
Last week, more than 25,650 participants received the second dose of the company’s vaccine, which is given in two doses. According to Moderna, 37% of participants are from diverse communities and 42% are at high risk of taking a severe form of Covid-19.
A proportion of 53% of the participants are men and 47% women, and the vast majority are over 25 years old. Only 5% are from the 18-24 age group.
The Modern Vaccine, which is being developed with the help of the National Institutes of Health, contains genetic material called messenger RNA or mRNA, which scientists hope will cause the immune system to fight the virus.
In August, Moderna announced that it was charging between $ 32 and $ 37 for a dose of vaccine to some customers as part of a low-cost policy during the pandemic. The company also said it is negotiating broader agreements, in which prices will be lower.
Moderna said on Thursday that the vaccine must be kept at minus 4 degrees Fahrenheit (-20 degrees Celsius), to be valid for six months.
By comparison, the Pfizer vaccine requires a storage temperature of minus 94 degrees Fahrenheit (-70 degrees Celsius).
The Modern vaccine can also be refrigerated at about 36 degrees Fahrenheit (2.2 degrees Celsius) for up to seven days. It must be administered within 12 hours after thawing.
Separately, the company reported a loss of $ 233.6 million, or 59 cents a share, in the third quarter, higher than the loss of 43 cents a share expected by analysts interviewed by Refinitiv. The company had revenues of $ 157.9 million, above the anticipated level of Wall Street, of $ 77.5 million.